TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07346859: Open-label, Multicentre, Tolerability, Safety and Pharmacokinetics Study of the Medicinal Product BP-SCIG 20% (Human Normal Immunoglobulin for Subcutaneous Administration) Manufactured by BIOPHARMA PLASMA LLC, Followed b

Sponsor: Biopharma Plasma LLC · Phase: PHASE3 · Area: IMMUNOLOGY · Target Enrollment: 56 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$6,564,660

Rescue Site Savings

+$4,311,120

Unlock Full NCT07346859 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07346859 Rescue Dossier →